Access to Diagnostics and Treatment for People With Metastatic EGFR-Positive NSCLC: Lessons From Project PRIORITY

Overview

Journal JTO Clin Res Rep

Date 2025 Feb 25

PMID 39996089

Authors

Jill Feldman

Ivy Elkins

Zofia Piotrowska

Bellinda L King-Kallimanis

Tendai Chihuri

Carly Johnson

Alecia Clary

Teri Kennedy

Upal Basu Roy

Affiliations

Soon will be listed here.

Abstract

Introduction: The treatment landscape for people diagnosed with EGFR-mutated (EGFR-m) NSCLC has rapidly evolved, yet there remains limited self-reported information about the lived experience. In this paper, we describe the clinical characteristics and treatment experiences of people living with EGFR-m lung cancer from Project PRIORITY, a patient-driven study.

Methods: An online survey was distributed among the EGFR Resisters community between April 2019 and January 2020. The survey captured participants' demographics and lung cancer risk factors, diagnostic and treatment pathways, and prevalence of side effects. Descriptive statistics were used and included subgroups based on residency and cancer stage.

Results: Of the 425 participants, most were female (67%), under 60 years old (53%), and resided in the United States (74%). The most frequently reported symptom at diagnosis was cough (54%), though 18% reported no symptoms. In addition, 89% reported receiving at least one tyrosine kinase inhibitor (TKI); osimertinib was the most prescribed first-line TKI for stage IV participants diagnosed after 2017. Participants residing in the United States were more likely to have access to advanced diagnostic (next-generating sequencing) and newer treatments such as osimertinib. Just under half of the sample (47%) had experienced progressive disease and were no longer on first-line treatment.

Conclusion: The TKI era has been practice changing; however, little is understood from the perspective of people living with EGFR-m NSCLC. This paper is the first to explore this and found it is possible to have people self-report complex health information about their lung cancer. In addition, although most participants were diagnosed after osimertinib became guideline-recommended treatment, disparities in treatment were identified.

References

Chouaid C, Filleron T, Debieuvre D, Perol M, Girard N, Dansin E . A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes. Target Oncol. 2021; 16(6):801-811. DOI: 10.1007/s11523-021-00848-9. View

Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M . Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009; 101(23):1624-32. PMC: 2786917. DOI: 10.1093/jnci/djp386. View

Scott J, Lennerz J, Johnson M, Gordan L, Dumanois R, Quagliata L . Compromised Outcomes in Stage IV Non-Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data. JCO Oncol Pract. 2023; 20(1):145-153. PMC: 10827288. DOI: 10.1200/OP.22.00611. View

Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I . EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101(36):13306-11. PMC: 516528. DOI: 10.1073/pnas.0405220101. View

Thai A, Solomon B, Sequist L, Gainor J, Heist R . Lung cancer. Lancet. 2021; 398(10299):535-554. DOI: 10.1016/S0140-6736(21)00312-3. View

Sun X, Zheng Y . Cisplatin or Carboplatin for advanced non-small-cell lung cancer?. J Thorac Oncol. 2014; 9(9):e70. DOI: 10.1097/JTO.0000000000000246. View

Zhou X, Cai L, Liu J, Hua X, Zhang Y, Zhao H . Analyzing EGFR mutations and their association with clinicopathological characteristics and prognosis of patients with lung adenocarcinoma. Oncol Lett. 2018; 16(1):362-370. PMC: 6006462. DOI: 10.3892/ol.2018.8681. View

Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris M . Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol. 2006; 7(11):903-9. DOI: 10.1016/S1470-2045(06)70910-X. View

Uyl-de Groot C, Heine R, Krol M, Verweij J . Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe. Cancers (Basel). 2020; 12(8). PMC: 7464890. DOI: 10.3390/cancers12082313. View

10.

Xiao C, Polomano R, Bruner D . Comparison between patient-reported and clinician-observed symptoms in oncology. Cancer Nurs. 2012; 36(6):E1-E16. DOI: 10.1097/NCC.0b013e318269040f. View

11.

Lee Y, Jeon J, Goh S, Roh H, Yun J, Kwon N . The clinical impact of family history of cancer in female never-smoker lung adenocarcinoma. Lung Cancer. 2019; 136:15-22. DOI: 10.1016/j.lungcan.2019.07.031. View

12.

Kastrati K, Mathies V, Kipp A, Huebner J . Patient-reported experiences with side effects of kidney cancer therapies and corresponding information flow. J Patient Rep Outcomes. 2022; 6(1):126. PMC: 9758261. DOI: 10.1186/s41687-022-00533-z. View

13.

Sheinson D, Wong W, Flores C, Ogale S, Gross C . Association Between Medicare's National Coverage Determination and Utilization of Next-Generation Sequencing. JCO Oncol Pract. 2021; 17(11):e1774-e1784. PMC: 8600504. DOI: 10.1200/OP.20.01023. View

14.

Lynch T, Bell D, Sordella R, Gurubhagavatula S, Okimoto R, Brannigan B . Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350(21):2129-39. DOI: 10.1056/NEJMoa040938. View

15.

Goulart B, Chennupati S, Fedorenko C, Ramsey S . Access to Tyrosine Kinase Inhibitors and Survival in Patients with Advanced EGFR and ALK Positive Non-small-cell Lung Cancer Treated in the Real-World. Clin Lung Cancer. 2021; 22(5):e723-e733. DOI: 10.1016/j.cllc.2021.01.019. View